In Vivo Effects of Prostaglandin Analogues Application by Topical Drops or Retrobulbar Injections on the Orbital Fat of a Rat Model

To assess the in vivo effects of bimatoprost 0.03% (Lumigan®) on the orbital fat in a rat model. Twenty rats were randomly divided into two groups: bimatoprost was administrated to the right eye by topical drops (group 1) or retrobulbar injection (group 2), and saline was administrated to the left e...

Full description

Saved in:
Bibliographic Details
Published in:Ocular immunology and inflammation 2023-02, Vol.31 (2), p.298-303
Main Authors: Jbara, Doha, Eiger-Moscovich, Maya, Didkovsky, Elena, Keshet, Yariv, Avisar, Inbal
Format: Article
Language:English
Subjects:
Adipose Tissue
Amides - pharmacology
Animals
Antihypertensive Agents
Bimatoprost
Bimatoprost - pharmacology
Cloprostenol - pharmacology
Eye
Intraocular Pressure
Orbit
orbital fat atrophy
Prostaglandins, Synthetic - pharmacology
rat model
Rats
thyroid eye disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the in vivo effects of bimatoprost 0.03% (Lumigan®) on the orbital fat in a rat model. Twenty rats were randomly divided into two groups: bimatoprost was administrated to the right eye by topical drops (group 1) or retrobulbar injection (group 2), and saline was administrated to the left eye by similar administration routes (controls). Four weeks later, all rats were sedated and euthanized, both orbits exenterated, and thin sections through the intraconal orbital fat were obtained. Average adipocyte cell count was significantly lower in the bimatoprost treated orbits (drops or retrobulbar injection, 29.5 vs. 67.5 cells per slide in the control globes, p=0.046). Fat cells were not detected in 9/20 (45%) bimatoprost treated orbits     . Orbits treated with bimatoprost by drops or retrobulbar injection demonstrated significant decrease in adipocytes cell count compared with controls. Bimatoprost could be an effective treatment for inactive thyroid eye disease.
ISSN:0927-3948
1744-5078
DOI:10.1080/09273948.2022.2026977